Segment Information (Tables)

6 Months Ended

Jun. 30, 2020

Schedule of segment information - net sales and operating earnings


	Net Sales to External Customers								Operating Earnings
	Three Months				Six Months				Three Months				Six Months
	Ended June 30				Ended June 30				Ended June 30				Ended June 30
(in millions)	2020		2019		2020		2019		2020		2019		2020		2019
Established Pharmaceutical Products	$	1,013	$	1,108	$	2,057	$	2,100	$	206	$	214	$	387	$	373
Nutritional Products		1,883		1,875		3,787		3,667		474		447		933		827
Diagnostic Products		1,994		1,905		3,820		3,746		522		466		927		900
Medical Devices		2,423		3,075		5,360		5,970		391		917		1,194		1,764
Total Reportable Segments		7,313		7,963		15,024		15,483		1,593		2,044		3,441		3,864
Other		15		16		30		31
Net sales	$	7,328	$	7,979	$	15,054	$	15,514
Corporate functions and benefit plan costs										(106)		(99)		(238)		(201)
Net interest expense										(125)		(146)		(246)		(294)
Share-based compensation (a)										(115)		(114)		(348)		(340)
Amortization of intangible assets										(553)		(483)		(1,114)		(969)
Other, net (b)										(168)		(100)		(336)		(326)
Earnings from continuing operations before taxes									$	526	$	1,102	$	1,159	$	1,734

(a)	Approximately 50 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.

(b)

Other, net for the three and six months ended June 30, 2020 and 2019 includes integration costs associated with the acquisition of St. Jude Medical and Alere, and restructuring charges. Other, net for the three and six months ended June 30, 2020 also includes impairments of equity investments. Other, net for the six months ended June 30, 2019 also includes a charge associated with an R&D asset acquired and immediately expensed.